Tarlatamab-dlle - IMDELLTRA | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

IMDELLTRA: official pharmacokinetics do not repair the partial RX page

The official selected section supplies renal pharmacokinetics, not a stand-alone dosing algorithm for severe impairment or dialysis. The RX rendering remains incomplete.

Before applying: Do not convert unchanged pharmacokinetics into an unrestricted no-adjustment recommendation; clarify the source eGFR units.

Also check: IMDELLTRA: official pharmacokinetics do not repair the partial RX page

Official source

Tarlatamab-dlle - IMDELLTRA

Product / population: IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.
Renal measure: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.

RX rendering remains incomplete and is not imported. Official label page update and PI revision are different dates.

Renal dosing, restrictions and evidence limits

No clinically important pharmacokinetic difference was reported with mild or moderate impairment, described as eGFR 30 to <90 mL/min. Effects in severe impairment, eGFR 15 to <30, and end-stage disease, eGFR <15, are unknown. These are pharmacokinetic findings, not a stand-alone no-adjustment recommendation or dialysis schedule.

Source revision: Prescribing information revised 11/2025. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Tarlatamab-dlle - IMDELLTRA

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.

Renal method: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

evidence limit

IMDELLTRA: official pharmacokinetics do not repair the partial RX page

The official selected section supplies renal pharmacokinetics, not a stand-alone dosing algorithm for severe impairment or dialysis. The RX rendering remains incomplete.

How to use this: Do not convert unchanged pharmacokinetics into an unrestricted no-adjustment recommendation; clarify the source eGFR units.

Tarlatamab-dlle - IMDELLTRA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Tarlatamab-dlle - IMDELLTRA

IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.

Method: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Tarlatamab-dlle - IMDELLTRA

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782

Exact product and population

IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.

RDM44-SCOPE-tarlatamab-imdelltra · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Tarlatamab-dlle - IMDELLTRA

Open original reference

Open / share this exact local source

DailyMed / Amgen Inc. · IMDELLTRA intravenous tarlatamab-dlle kit; selected pharmacokinetic renal information only, not a step-up dosing or toxicity-management protocol.

Renal method: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.
Source date: Prescribing information revised 11/2025.
Retrieved: 2026-09-08

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM44-official-tarlatamab-imdelltra-2f053beddf-C1 · Source locator: Section 12.3: Specific Populations, lines 924-925.

Source-specific limits

RX rendering remains incomplete and is not imported. Official label page update and PI revision are different dates.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782
Retrieved: 2026-09-08
Exact label title: Tarlatamab-dlle - IMDELLTRA
DailyMed Set ID: 1e7b6163-5d83-42ea-82c9-cf7620cdc782
Labeler: Amgen Inc.
DailyMed page updated: 2026-06-23
Label revision: Prescribing information revised 11/2025.
Archive publication date: 2026-07-20
SPL version: 7
FDA application: BLA761344
Renal-function method: Source prints eGFR in mL/min without a BSA denominator; indexed versus nonindexed meaning is not resolved here.
Source date/version: Prescribing information revised 11/2025.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 4a1571e1d72bdffaece124314c29603d6a38de6b5604db831dd56bbcbf9204f8

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e7b6163-5d83-42ea-82c9-cf7620cdc782
Source retrieval: 2026-09-08. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: 01e37af0f23dcf45b5ba34418dd6acd7b7da49e4a9c1bd290250976d9fc37f91
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report